$AEHR

SLAYEN HOWARD T sold $758K of AEHR

SLAYEN HOWARD T (Director) sold 5,700 shares of AEHR TEST SYSTEMS (AEHR) at $133.03 ($0.76M total) on 2026-08-14.

Original reporting
SEC EDGAR · SLAYEN HOWARD T
Published Aug 14, 2026, 9:52 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 10:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AEHR
Neutral
medium confidence
Mentioned
$AEHR
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AEHRNeutralLow
01

Why it matters

This provides a fresh datapoint on insider behavior but does not disclose new operational, financial, or regulatory information about AEHR.

02

Market read

Traders may briefly reassess sentiment around AEHR due to insider selling, but there is no fundamental catalyst in the text.

03

What to watch

The filing does not state motivations, and the transaction is an open-market sale. Also, insider selling can occur alongside positive fundamentals, so traders should watch for follow-on Form 4 patterns rather than react once.

Relevance 5/10Novelty 3/10Timing: filed on 2026-08-14, after-hours SEC Form 4 disclosure

Background

The article is an SEC Form 4 insider transaction disclosure for AEHR, reported as an open-market sale by a director.

Company-level read

Ticker impact

$AEHRNeutralMedium confidence
Context

Director Slayen Howard T filed an open-market sale of 5,700 AEHR shares for about $758K on 2026-08-14.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and should fade unless follow-on selling appears.

Evidence & confidence

The filing is a Form 4 insider transaction, but it does not include new company fundamentals, guidance, or regulatory/contract events. The absence of a 10b5-1 plan can increase interpretive noise, yet the disclosed size is not large enough to imply a structural shift by itself.

Market effects

No clear sector read-through; this is company-specific insider activity without operational or regulatory linkage.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity or diversification; without evidence of broader selling or performance deterioration, the signal may be overstated.

Key entities

  • AEHR TEST SYSTEMS

    Subject of the Form 4 insider transaction disclosure.

  • SLAYEN HOWARD T

    Director who sold 5,700 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AEHRMed

AEHR Stock Rides AI Order Wave Amid Volatility

Aehr Test Systems (AEHR) stock rose 13.28% following strong earnings and a positive outlook for semiconductor test demand. The company reported $50M in revenue, $18.8M in quarterly revenue, and a net income of $1.39M. Jefferies initiated coverage with a Buy rating and $175 price target, citing AEHR's role in AI production. The stock has shown volatility, with a recent drop of 9.5-10.5% in a single session. Insiders have sold shares but maintain significant holdings. AEHR is actively presenting a

$AEHRHigh

AEHR Stock Rallies As AI Orders And Wall Street Support Build

Aehr Test Systems (AEHR) stock rose 11.71% due to strong AI-related demand. The company reported $18.8M in revenue with a 35.3% gross margin. Jefferies initiated coverage with a Buy rating and $175 price target, citing AEHR's role in AI chip production. The company has a strong balance sheet and a $22M follow-on order from a major customer.

$AEHRHigh

AEHR Stock Rallies As AI Test Orders And Wall Street Support Grow

Aehr Test Systems (NASDAQ: AEHR) stock rose 11.73% on growing AI test demand. The company secured a $22M follow-on order for AI chip testing equipment. Jefferies initiated coverage with a Buy rating and $175 price target, citing AEHR's unique position in AI production testing. The stock has high volatility, with a strong balance sheet but negative EBIT margins.